A set of ~500 purified natural product compounds was screened for inhibition against the human pathogen Mycobacterium tuberculosis. A series of cyclic hexapeptides with antitubercular activity was identified. Five analogs from a set of sixteen closely related compounds were active, with minimum inhibitory concentrations ranging from 2.3-8.9 µM.
Tuberculosis remains a global health problem, with an increasing number of new cases (10.4 million in 2015) and an increasing problem of drug resistance (1). New therapeutic agents which act against novel bacterial targets are needed to supplement and supplant the current drugs. Therefore there is great interest in finding new chemical matter that has activity against the causative agent, Mycobacterium tuberculosis. A large effort has been expended to examine small molecule libraries as starting point for drug discovery (2, 3) . Less attention has been paid to natural products as starting points for a discovery program. We were interested in expanding chemical diversity to identify novel inhibitors which could be used either as starting points for a drug discovery program or as probes to identify novel targets. Growth inhibition curves were plotted using the Levenberg-Marquardt algorithm and the concentration that resulted in 90% inhibition of growth was determined (MIC90). For active compounds, assays were conducted at least twice. Rifampicin was used as a control in each plate -for comparison the MIC of rifampicin was 0.0077 µM.
From these experiments, MSD-453 confirmed as a hit and further analogs based on similarity searches were ordered and tested. The initial hit, a cyclic hexapeptide, cyclo[N-(Me)Phe-Pro-Phe-N-(OH)Leu-Piz-Piz] (compound 1) had good activity against M. tuberculosis, with an MIC90 of 2.3 µM (Table 1) (13) (14) . The combined replacement of N-methylphenylalanine with norvaline and phenylalanine with leucine also removed activity (16, MIC90 > 20 µM). Based on these analogs, we were able to determine some limited structure-activity relationship ( Figure   1 ). Although the compounds were not as potent as rifampicin, they did have good activity, with a dynamic SAR ranging from low micromolar to inactive (>20 µM).
The original hit molecule, MSD-453, along with several congeners (10-13) and synthetic analogs (11) (12) (13) (14) (15) , were originally identified as sub-micromolar to low nanomolar oxytocin receptor antagonists. M. tuberculosis does not have a homolog of this receptor; thus, this series appears to have a different target in the pathogen.
In an attempt to identify the M. tuberculosis biochemical target, resistant mutants to two of the compounds were isolated. The potency of each compound on Middlebrook 7H10 medium containing 10% v/v OADC supplement was measured. MIC99 values were determined by the serial proportion method and defined as the minimum concentration required to prevent 99% growth on solid medium (7) . Under these incubation conditions, the MIC99 was 1.6 µM and 0.8 µM for MSD-045 and MSD-099 respectively ( Table 2) .
Resistant mutants were isolated on Middlebrook 7H10 plus 10% v/v OADC at 5X MIC of each compound after 3-4 weeks growth (8) . Colonies were tested for MIC99 on solid medium to confirm resistance ( Table 2 ). In this longer term assay on solid media both compounds showed better potency than when tested for shorter time (5d) assay in liquid media (Table 1) . Although nine confirmed resistant isolates were subjected to whole genome sequencing (9) , no mutations were observed in 8 of the strains. Strain LP-0458686-RM1 had two mutations, one in gap (Rv1436) and one in Rv1543, but these were not observed in any of the other eight strains. Thus no genotypic explanation for the observed resistance was determined. In this case, the resistance phenotype could be due to epigenetic phenomena.
In conclusion, a series of cyclic natural product peptides with activity against M. (7) . 
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